Delayed London S.E. 12:35:09 2024-03-28 pm EDT 5-day change 1st Jan Change
8.1 GBX -6.36% Intraday chart for IXICO plc -1.82% -35.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ixico shares fall 20% as revenue to decline, hit by delays to projects AN
AIM WINNERS & LOSERS: Woodbois rises as plots Mozambique exit AN
FTSE 100 slips but CAC and DAX hit record highs AN
Ixico CEO Cerroni to retire by end of 2024; starts succession search AN
Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024 CI
Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024 CI
Transcript : IXICO plc, 2023 Earnings Call, Dec 05, 2023
EARNINGS AND TRADING: Ixico revenue falls, Solid State boosts profit AN
IXICO plc Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees CI
EARNINGS AND TRADING: Barkby revenue dips; Ixico hurt by trial delays AN
IXICO plc Provides Earnings Guidance for the Full Year of 2023 CI
Andrada raises GBP7.7 million; Ixico signs contract AN
IXICO plc Announces Contract Win for A Phase 3 Progressive Supranuclear Palsy Study CI
IXICO Receives New GBP2 Million Imaging Services Contract MT
Ixico wins Huntington's disease contract worth GBP2 million AN
IXICO plc Announces Contract Win in Huntington's Disease CI
Transcript : IXICO plc, H1 2023 Earnings Call, May 23, 2023
Ixico shares drop as firm swings to interim loss on cancelled trials AN
Earnings Flash (IXI.L) IXICO Posts Fiscal H1 Revenue GBP3.2M MT
Earnings Flash (IXI.L) IXICO Reports Fiscal H1 Loss GBX-1.50 MT
IXICO plc Reports Earnings Results for the Half Year Ended March 31, 2023 CI
Ixico remains positive despite expected swing to interim loss AN
IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024 CI
Ixico extends Huntington's consortium with GBP1 million contracts AN
Chart IXICO plc
More charts
IXICO plc is a United Kingdom-based company that provides specialist data analytics services to the global biopharmaceutical industry. The services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. The outputs from the data analysis are used to enhance patient selection, monitor drug safety, and assess clinical efficacy of the drug under development. It offers a range of services, such as drug development analytics, imaging operations, post-marketing, and post-marketing. It offers end to end services, including trial design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. It offers a range of clinical trial imaging analysis tools, including radiological reads, structural and advanced magnetic resonance imaging (MRI). Its specialist data analytics services identify and measure biomarkers from brain scans and wearable biosensors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock IXICO plc - London S.E.
  4. News IXICO plc
  5. IXICO : Earnings Flash (IXI.L) IXICO Posts FY20 EPS GBX2.00